

Cover Story
By Matthew Bin Han Ong
Moving away from recommendations dating back to 2009, the U.S. Preventive Services Task Force now states that women should start biennial screening for breast cancer at age 40—instead of 50—a change that experts say is based on new, inclusive science.
In Brief
Clinical Roundup


Drugs & Targets
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

















